Similarly, our research group conducted a preliminary study showing that an engineered OVV expressing an anti-CD47 nanobody improves efficacy against lymphoma by promoting macrophage phagocytosis of CD47+ tumors and NK-cell-mediated antibody-dependent cellular cytotoxicity. Here, CD47 is linked to lymphoma.